Co-Diagnostics (CODX) earnings

Co-Diagnostics, Inc.· Health Care

Results to: Jun 2026
Latest analysed call: Jun 2026 (Q2 FY26)
Balance sheet to: Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Co-Diagnostics earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	0.17 $ million	+2.0% YoY	Quarterly, as filed	Quarter to Jun 2026	Revenue from operations as filed.
Operating margin	-3732.5 %	+1213.7 pts YoY	Operating profit / revenue	Quarter to Jun 2026	For the quarter; a change is in percentage points.
Net profit	-6.3 $ million	—	Quarterly, as filed	Quarter to Jun 2026	Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Price

$0.67 +3.08% · +$0.02

Last close Oct 19, 2026 · US · USD

Performance −93.1% 1Y

1Y: $9.72 on 17 Oct 2025 → $0.67. High $37.8 (27 Oct 2025), low $0.65 (16 Oct 2026).

Previous close: $0.65
52-week range: $0.65 – $37.8
One year: −93.55%

Overview

Symbol: CODX
Sector: Health Care
Exchange: US
Currency: USD

Financials

What the filings say

Net profit, year on year: +19% (quarter to jun 2026 against jun 2025).

In $ million. Oldest period first.

Line item	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	1	0	0	0	0	0	0	0
Operating profit	-10	-12	-9	-8	-7	-27	-9	-6
Operating margin	−1596.4%	−7973.9%	−17009.7%	−4946.1%	−4824.5%	−10056.7%	−6309.1%	−3732.5%
Other income	1	1	1	0	-0	0	0	-0
Profit before tax	-10	-11	-8	-8	-7	-26	-9	-6
Tax rate	−0.2%	0.1%	−0.2%	−0.2%	16.5%	1.8%	−0.0%	−0.3%
Net profit	-10	-11	-8	-8	-6	-26	-9	-6
EPS ($ per share)	-0.32	—	-7.05	-7	-0.16	—	-4.06	-1.46

Source: Inve data · income statement, quarterly · to Jun 2026

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Equity capital	0	0	0	0	0	0	0	0
Reserves	-19	-25	18	54	40	5	-33	-80
Total liabilities	3	0	5	26	9	9	10	4
Fixed assets	0	0	1	2	3	3	3	2
Investments	—	—	4	1	58	44	27	—
Total assets	2	2	71	160	123	95	64	25

Source: Inve data · balance sheet · to Dec 2025

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from operations	-4	-6	28	41	7	-22	-29	-29
Cash from investing	-0	-0	-6	4	-58	15	17	26
Cash from financing	2	6	20	0	-14	-1	0	12
Net cash flow	-3	-0	42	46	-66	-8	-12	9
Capital expenditure	-0	-0	-1	-1	-1	-1	-1	-1
Free cash flow	-4	-6	27	40	5	-23	-30	-30

Source: Inve data · cash flow · to Dec 2025

Insider filings

20 filings between Nov 23, 2025 and May 23, 2026.

Open market

decisions to buy or sell

Nobody bought or sold CODX on the open market in this window. The filings below are 14 awards and 6 dispositions to the issuer.

Compensation

not trading decisions

14: Award — granted as compensation

Latest filings (40)

Date	Insider	What	Shares	Value
May 23, 2026	SERBIN RICHARD S Director	Award	1,695	$0
May 23, 2026	NELSON JAMES B Director	Award	1,695	$0
May 23, 2026	Egan Dwight H Chief Executive Officer	Award	4,584	$0
May 23, 2026	Egan Dwight H Chief Executive Officer	Disposition to issuer	1,633	$8.3K
May 23, 2026	Murphy Edward L. Director	Award	1,695	$0
May 23, 2026	Durenard Eugene Director	Award	1,695	$0
May 23, 2026	Brown Brian Lee Chief Financial Officer	Award	3,750	$0
May 23, 2026	Brown Brian Lee Chief Financial Officer	Disposition to issuer	1,350	$6.8K
May 23, 2026	Abbott Richard David President	Award	1,890	$0
May 23, 2026	Abbott Richard David President	Disposition to issuer	680	$3.4K
Nov 23, 2025	SERBIN RICHARD S Director	Award	57,499	$0
Nov 23, 2025	NELSON JAMES B Director	Award	57,499	$0
Nov 23, 2025	Egan Dwight H Chief Executive Officer	Award	163,333	$0
Nov 23, 2025	Egan Dwight H Chief Executive Officer	Disposition to issuer	49,575	$17.4K
Nov 23, 2025	Murphy Edward L. Director	Award	57,499	$0
Nov 23, 2025	Durenard Eugene Director	Award	57,499	$0
Nov 23, 2025	Brown Brian Lee Chief Financial Officer	Award	134,167	$0
Nov 23, 2025	Brown Brian Lee Chief Financial Officer	Disposition to issuer	40,723	$14.3K
Nov 23, 2025	Abbott Richard David President	Award	56,667	$0
Nov 23, 2025	Abbott Richard David President	Disposition to issuer	17,200	$6.0K
May 23, 2025	NELSON JAMES B Director	Award	48,334	$0
May 23, 2025	Durenard Eugene Director	Award	48,334	$0
May 23, 2025	MURPHY TED Director	Award	48,334	$0
May 23, 2025	SERBIN RICHARD S Director	Award	48,334	$0
May 23, 2025	Abbott Richard David President	Award	20,000	$0
May 23, 2025	Abbott Richard David President	Disposition to issuer	7,180	$1.7K
May 23, 2025	Brown Brian Lee Chief Financial Officer	Award	134,166	$0
May 23, 2025	Brown Brian Lee Chief Financial Officer	Disposition to issuer	48,161	$11.6K
May 23, 2025	Egan Dwight H Chief Executive Officer	Award	163,334	$0
May 23, 2025	Egan Dwight H Chief Executive Officer	Disposition to issuer	51,697	$12.4K
Nov 23, 2024	SERBIN RICHARD S Director	Award	48,333	$0
Nov 23, 2024	NELSON JAMES B Director	Award	48,333	$0
Nov 23, 2024	Durenard Eugene Director	Award	48,333	$0
Nov 23, 2024	MURPHY TED Director	Award	48,333	$0
Nov 23, 2024	Egan Dwight H Chief Executive Officer	Award	163,333	$0
Nov 23, 2024	Egan Dwight H Chief Executive Officer	Disposition to issuer	49,689	$50.2K
Nov 23, 2024	Abbott Richard David President	Award	20,000	$0
Nov 23, 2024	Abbott Richard David President	Disposition to issuer	6,085	$6.1K
Nov 23, 2024	Brown Brian Lee Chief Financial Officer	Award	134,167	$0
Nov 23, 2024	Brown Brian Lee Chief Financial Officer	Disposition to issuer	40,816	$41.2K

Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.

Your own record

Start an Inve Case for Co-Diagnostics, Inc.

Free account. Everything above stays public.

Write why you follow Co-Diagnostics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading